Akebia Therapeutics, Inc. (AKBA)

Market Cap	463.01M
Revenue (ttm)	160.18M
Net Income (ttm)	-69.41M
Shares Out	236.23M
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,875,863
Open	2.020
Previous Close	2.040
Day's Range	1.900 - 2.030
52-Week Range	0.800 - 2.890
Beta	0.94
Analysts	Strong Buy
Price Target	6.75 (+244.39%)
Earnings Date	Mar 13, 2025

About AKBA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Mar 20, 2014
• Employees: 181
• Stock Exchange: NASDAQ
• Ticker Symbol: AKBA
• Website: https://www.akebia.com

Financial Performance

In 2024, Akebia Therapeutics's revenue was $160.18 million, a decrease of -17.70% compared to the previous year's $194.62 million. Losses were -$69.41 million, 33.7% more than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for AKBA stock is "Strong Buy." The 12-month stock price forecast is $6.75, which is an increase of 244.39% from the latest price.

Price Target

$6.75

(244.39% upside)

Analyst Consensus: Strong Buy